FIELD: medicine.SUBSTANCE: group of inventions relates to field of medicine and is intended for treatment of multiple sclerosis (MS). Claimed is method of treating multiple sclerosis (MS) in patient who was first treated by means of MS-therapy with drugs different from alemtuzumab, including introduction of 1-12 mg/day of alemtuzumab to patient for 1-5 days as initial treatment course and at least 3 months after initial treatment course introduction of 1-12 mg/day of alemtuzumab to patient for 1-5 days as second treatment course. Claimed is method for reducing number of lymphocytes in patient with multiple sclerosis (MS), with said patient first being treated by means of MS-therapy with medications different from alemtuzumab, including introduction of 1-12 mg/day of alemtuzumab to patient for 1-5 days as initial treatment course and at least 3 months after initial treatment course introduction of 1-12 mg/day of alemtuzumab to patient for 1-5 days as second treatment course. Claimed is method of reducing risk of recurrence or risk of development of clinically significant disability in patients with multiple sclerosis, with said patient first being treated by means of MS-therapy with medications different from alemtuzumab, including introduction of 1-12 mg/day of alemtuzumab to patient for 1-5 days as initial treatment course at least 3 months after initial treatment course introduction of 1-12 mg/day of alemtuzumab to patient for 1-5 days as second treatment course. Claimed is method of treating multiple sclerosis (MS) in patient who was first treated by means of MS-therapy with drugs different from alemtuzumab, including introduction of 10-60 mg of alemtuzumab to patient for 1-5 days as initial treatment course and at least 3 months after initial treatment course introduction of 10-60 mg of alemtuzumab to patient for 1-5 days as second treatment course. Claimed is method for treating recurrences of multiple sclerosis (MS) in patient who first was treated by means of
